PharmGen Science マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some Risk

Aug 12

PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 27

Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?

Mar 21

Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%

Jan 19

Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?

Dec 21

Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 25

CEO（最高経営責任者

PharmGen Science CEOがいない、あるいは彼らに関するデータがない。

PharmGen Science マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Wooridul Pharmaceutical Limited, Annual General Meeting, Mar 25, 2021

Recent updates

PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some Risk

PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings released: EPS: ₩352 (vs ₩4,498 in FY 2022)

New minor risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings released: EPS: ₩4,498 (vs ₩2,206 in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

PharmGen Science Inc. announced that it has received KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited

Investor sentiment deteriorated over the past week

PharmGen Science Inc. announced that it expects to receive KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?

Full year 2020 earnings released: EPS ₩675 (vs ₩26.00 in FY 2019)

Wooridul Pharmaceutical Limited, Annual General Meeting, Mar 25, 2021

New 90-day low: ₩9,180

New 90-day low: ₩9,340

Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%

New 90-day low: ₩10,350

Investor sentiment deteriorated over the past week

New 90-day low: ₩11,800

Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?

New 90-day low: ₩11,900

Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?

New 90-day low: ₩12,250

Wooridul Pharmaceutical Limited announced that it expects to receive KRW 20 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited

New 90-day high - ₩20,300

New 90-day high - ₩7,380

CEO（最高経営責任者

PharmGen Science マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Wooridul Pharmaceutical Limited, Annual General Meeting, Mar 25, 2021

Recent updates

PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some Risk

PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings released: EPS: ₩352 (vs ₩4,498 in FY 2022)

New minor risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings released: EPS: ₩4,498 (vs ₩2,206 in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

PharmGen Science Inc. announced that it has received KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited

Investor sentiment deteriorated over the past week

PharmGen Science Inc. announced that it expects to receive KRW 30 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?

Full year 2020 earnings released: EPS ₩675 (vs ₩26.00 in FY 2019)

Wooridul Pharmaceutical Limited, Annual General Meeting, Mar 25, 2021

New 90-day low: ₩9,180

New 90-day low: ₩9,340

Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%

New 90-day low: ₩10,350

Investor sentiment deteriorated over the past week

New 90-day low: ₩11,800

Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?

New 90-day low: ₩11,900

Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?

New 90-day low: ₩12,250

Wooridul Pharmaceutical Limited announced that it expects to receive KRW 20 billion in funding from Linden Advisors LP, SC Lowy Financial (HK) Limited

New 90-day high - ₩20,300

New 90-day high - ₩7,380

CEO（最高経営責任者

マネジメント基準チェック /04